[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335350-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335350-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","revisiting-the-association-between-pretreatment-thrombocytosis-and-cancer-survival-outcomes-an-umbrella-review-of-meta-analyses","Revisiting the association between pretreatment thrombocytosis and cancer survival outcomes - an umbrella review of meta-analyses","","Association studies have linked pretreatment thrombocytosis with cancer survival outcomes, yet the validity and strength of the underlying observational evidence remain disputed. An umbrella review was conducted to appraise the strength, validity, and credibility of these reported associations by retrieving meta-analyses of observational studies from major databases. Random-effect re-analyses were performed and evidence strength was graded using seven quantitative criteria, with review quality assessed via AMSTAR2 and reporting aligned with PRISMA. Results included 21 meta-analyses across 10 cancer subtypes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/revisiting-the-association-between-pretreatment-thrombocytosis-and-cancer-survival-outcomes-an-umbrella-review-of-meta-analyses/335350/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/revisiting-the-association-between-pretreatment-thrombocytosis-and-cancer-survival-outcomes-an-umbrella-review-of-meta-analyses/335350.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the goal of the umbrella review?","Question",{"text":63,"@type":64},"To comprehensively appraise the strength, validity, and credibility of reported associations between pretreatment thrombocytosis and cancer survival outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the included meta-analyses selected and re-analyzed?",{"text":68,"@type":64},"Meta-analyses of observational studies were retrieved from Medline, Embase, and Cochrane Database of Systematic Reviews up to 8 April 2023, then re-performed using a random-effect model.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the review find about patient survival outcomes?",{"text":72,"@type":64},"All included meta-analyses reported inferior survival outcomes in cancer patients with pretreatment thrombocytosis, and 18 of 21 showed statistically significant results.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335350,1790121049,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Shu et al. BMC Cancer (2024) 24:1246 [https://doi.org/10.1186/s12885-024-13027-6](https://doi.org/10.1186/s12885-024-13027-6)  \nBMC Cancer  \n SYSTEMATIC REVIEW Open Access  \nRevisiting the association    \nbetween pretreatment thrombocytosisand cancer survival outcomes: an umbrella review of meta-analyses  \nChi Shu1,2†, Xiran Wang3†, Changtao Li2, Jun Huang4,5, Xuan Xie2, Hong Li2, Jichun Zhao1, Ziqiang Wang4, Yazhou He2,5 andYanhong Zhou6*  \nAbstract  \nBackground Although associations have been reported linking pretreatment thrombocytosis to cancer survival outcomes, the validity and strength of existing observational evidence have been contested. This study aimed to conduct an umbrella review to comprehensively appraise the strength, validity and credibility of these reported associations.  \nMethods We searched Medline, Embase and Cochrane Database of Systematic Reviews from inception to 8 April 2023 to retrieve meta-analyses of observational studies. Meta-analyses were re-performed using a random-effect model and the strength of evidence was graded as convincing, highly suggestive, suggestive and weak according to seven pre-defined quantitative criteria reflecting statistical significance, amount of data, heterogeneity, and evidence of bias. The quality of review was appraised using the AMSTAR2 checklist. The umbrella review was reported adhering to the PRISMA guideline and was registered on PROSPERO (CRD42023455391) .  \nResults A total of 21 unique meta-analyses investigating ten cancer subtypes were included. All meta-analyses reported inferior survival outcome in cancer patients with pretreatment thrombocytosis, and 18 of them (85 . 7%) yielded statistically significant results (P \u003C 0. 05) . Consistent effects were observed across meta-analyses that adopted different cut-off values (i. e. platelet count > 300 or 400 × 109 /L) to define thrombocytosis. Although evidence appraisal did not identify convincing evidence (Class I), the associations of thrombocytosis with inferior overall survival of lung, gastric, colorectal cancer and malignant mesothelioma were classified as highly suggestive evidence (Class II) . According to AMSTAR2 ratings, no meta-analysis was identified with high or moderate quality.  \nConclusions Our findings consolidated the association between pretreatment thrombocytosis and poor survival outcomes in various cancers. Nonetheless, the absence of convincing associations indicates a need for further largescale, high-quality evidence to confirm whether platelets can serve as a prognostic predictor or a therapeutic target. Keywords Thrombocytosis, Cancer, Prognosis, Survival outcomes, Umbrella review  \n†Chi Shu and Xiran Wang contributed equally to this work.  \n*Correspondence:  \nYanhong Zhou  \n[yanhong_zhou2013@163.com](yanhong_zhou2013@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http:/","cbCaiuhU9L1nv5vQ","https://ap.wps.com/l/cbCaiuhU9L1nv5vQ","pdf",1229958,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Cancer burden and need for prognostic markers\n## Biological rationale for thrombocytosis\n## Study variability and inconsistency","[{\"question\":\"What was the goal of the umbrella review?\",\"answer\":\"To comprehensively appraise the strength, validity, and credibility of reported associations between pretreatment thrombocytosis and cancer survival outcomes.\"},{\"question\":\"How were the included meta-analyses selected and re-analyzed?\",\"answer\":\"Meta-analyses of observational studies were retrieved from Medline, Embase, and Cochrane Database of Systematic Reviews up to 8 April 2023, then re-performed using a random-effect model.\"},{\"question\":\"What did the review find about patient survival outcomes?\",\"answer\":\"All included meta-analyses reported inferior survival outcomes in cancer patients with pretreatment thrombocytosis, and 18 of 21 showed statistically significant results.\"}]","Revisiting the association between pretreatment thrombocytosis and cancer survival outcomes - an umbrella review of meta-analyses | PDF",1790010652,25]